About Ethanolamine-phosphate cytidylyltransferase
Ethanolamine-phosphate cytidylyltransferase (PCYT2) is a protein
from Homo sapiens identified by UniProt accession
Q99447, 389 residues long.
MolForge cross-references it against 0 known binders and
65 disease associations.
Target properties
| Protein name | Ethanolamine-phosphate cytidylyltransferase |
| UniProt accession | Q99447 |
| Gene | PCYT2 |
| Organism | Homo sapiens |
| Length | 389 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (65)
Diseases linked to this target (Open Targets).
- spastic paraplegia 82, autosomal recessive · score 0.73
- complex hereditary spastic paraplegia · score 0.55
- neurodegenerative disease · score 0.54
- Global developmental delay · score 0.46
- Intellectual disability · score 0.46
- Seizure · score 0.46
- Developmental regression · score 0.46
- Cerebellar atrophy · score 0.46
- Spastic paraparesis · score 0.46
- Cerebral atrophy · score 0.46
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q99447-F1 | alphafold | PREDICTED | 86.08 | — |
Amino-acid sequence (389 residues)
MIRNGRGAAG GAEQPGPGGR RAVRVWCDGC YDMVHYGHSN QLRQARAMGD YLIVGVHTDE EIAKHKGPPV FTQEERYKMV QAIKWVDEVV PAAPYVTTLE TLDKYNCDFC VHGNDITLTV DGRDTYEEVK QAGRYRECKR TQGVSTTDLV GRMLLVTKAH HSSQEMSSEY REYADSFGKC PGGRNPWTGV SQFLQTSQKI IQFASGKEPQ PGETVIYVAG AFDLFHIGHV DFLEKVHRLA ERPYIIAGLH FDQEVNHYKG KNYPIMNLHE RTLSVLACRY VSEVVIGAPY AVTAELLSHF KVDLVCHGKT EIIPDRDGSD PYQEPKRRGI FRQIDSGSNL TTDLIVQRII TNRLEYEARN QKKEAKELAF LEAARQQAAQ PLGERDGDF
Explore Ethanolamine-phosphate cytidylyltransferase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets